Grifols, S.A. is engaged in the acquisition, manufacture, preparation and sale of therapeutic products, mainly plasma derivatives. The company operates through the bioscientific, hospital, diagnostic, biosupplies and other divisions.
Grifols, S.A. engages in the acquisition, manufacture, preparation and sale of therapeutic products, principally plasma derivatives. The company operates through the Bioscience, Hospital, Diagnostics, Bio Supplies and Others segments. Revenue TTM 5.6B Net Income TTM 208M EBITDA TTM 894M EBITDA margin 15.9%.
Looks like an overall good company, solid financials & healthy balance sheet.
GRFS: Grifols 2019-02-07 12:31:00 Grifols Receives FDA Approval for Procleix Babesia Assay for Donor Screening on Procleix Panther System
GRFS: Grifols 2018-08-16 08:00:00 Grifols Achieves Key Milestone with FDA Approval of the New Consolidated Manufacturing Facility (CMF) for Production of Recombinant Proteins
Enter now at the flag break with stop below the LOD on the day of breakout